Topic: Renal and Urogenital
Conditions
Interventions
Control: Rexeed Dialyser
Intervention: Vitabran E dialyser
Follow Up Length: 12 month(s)
Sponsors
Leeds Teaching Hospitals NHS Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Dialysis patient managed by Leeds Teaching Hospitals NHS Trust Renal Unit 2. Established on HD for at least 3 months prior to entry into study 3. Patients expected to remain on haemodialysis for at least 6 months 4. Written consent and willingness to participate in the study 5. Aged greater than 18 years at point of entry into study 6. Patients on a 3 times a week dialysis schedule
Exclusion criteria
Exclusion criteria: 1. Unwillingness or inability to cooperate or give written informed consent 2. Terminally ill patients (expected survival less than 6 months) 3. Medical conditions requiring regular blood transfusion at the time of study enrolment 4. Any serious medical, social or psychological condition that in the opinion of the investigator would disqualify from participation 5. Patients with a significant inflammatory illness within 3 months as defined by a C-reactive protein (CRP) greater than 50 mg/L or 3 x patient's baseline CRP
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Haemoglobin concentration and erythropoeisis stimulating agent requirements at 6 months and 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Data collected at 6 and 12 months on: 1. Markers of oxidative stress 2. Fibrin clot structure | — |
Countries
United Kingdom
Outcome results
None listed